BioXcel Therapeutics Files 8-K
Ticker: BTAI · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 8-K, disclosure, regulatory-filing
TL;DR
BioXcel filed an 8-K on Feb 28, 2025. Check for details.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting an event on February 28, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes within the provided text. The company is incorporated in Delaware and headquartered in New Haven, CT.
Why It Matters
This filing indicates a routine update or event disclosure by BioXcel Therapeutics, requiring investors to check the full document for specific details not immediately apparent in the summary.
Risk Assessment
Risk Level: low — The filing is a standard 8-K 'Other Events' disclosure and does not immediately reveal significant financial or operational risks.
Key Numbers
- 001-38410 — Commission File Number (Identifier for the company's SEC filings)
- 82-1386754 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- February 28, 2025 (date) — Earliest event date
- March 3, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- New Haven, CT (location) — Principal executive offices
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The provided text for the 8-K filing does not specify the exact nature of the 'Other Events' beyond the general categorization.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 28, 2025.
What is BioXcel Therapeutics, Inc.'s principal executive office address?
BioXcel Therapeutics, Inc.'s principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
What is the company's telephone number?
The company's telephone number is (475) 238-6837.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).